Last reviewed · How we verify
No depression and estrogen treatment
No depression and estrogen treatment is a Small molecule drug developed by University of Pennsylvania. It is currently FDA-approved.
At a glance
| Generic name | No depression and estrogen treatment |
|---|---|
| Sponsor | University of Pennsylvania |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients (PHASE1)
- Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen (NA)
- Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No depression and estrogen treatment CI brief — competitive landscape report
- No depression and estrogen treatment updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI
Frequently asked questions about No depression and estrogen treatment
What is No depression and estrogen treatment?
No depression and estrogen treatment is a Small molecule drug developed by University of Pennsylvania.
Who makes No depression and estrogen treatment?
No depression and estrogen treatment is developed and marketed by University of Pennsylvania (see full University of Pennsylvania pipeline at /company/university-of-pennsylvania).
What development phase is No depression and estrogen treatment in?
No depression and estrogen treatment is FDA-approved (marketed).